OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of concentration of revenue

The following counterparties contributed greater than 10% of our total revenue during at least one of the periods set forth below. The revenue from these counterparties as a percentage of total revenue was as follows:

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2019		2018		2019		2018
Loxo Oncology	—	%	3.6	%	22.7	%	5.9	%
Pierre Fabre	19.0	%	9.2	%	19.9	%	10.6	%
Novartis Pharmaceutical	14.2	%	37.3	%	14.7	%	47.2	%
ASLAN	—	%	34.7	%	—	%	16.6	%
Total	33.2	%	84.8	%	57.3	%	80.3	%

Schedule of revenue by geographic area

The following table details revenue by geographic area based on the country in which our partners, Customers or license holders are located (in thousands):

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2019		2018		2019		2018
North America	$	37,877	$	4,682	$	126,102	$	14,845
Europe	21,461		33,744		70,596		82,892
Asia Pacific and Other	5,339		27,941		7,438		40,594
Total	$	64,677	$	66,367	$	204,136	$	138,331